Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Intestine Cancer Therapeutics Market Size Changed, over the years?

In recent years, the market size for intestine cancer therapeutics has seen significant growth. Its value is projected to rise from $14 billion in 2024 to $15.26 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to this historical growth trend include medical research advancements, a rise in cancer incidence, the use of chemotherapy and radiation therapies, initiatives for screening and early detection, and breakthroughs in genetic and biomarker research.

How Much Will the Intestine Cancer Therapeutics Market Be Worth in 2029?

The market for therapeutics associated with intestine cancer is anticipated to experience significant enlargement in the upcoming years. Expected to reach a value of $21.15 billion in 2029 with a compound annual growth rate (CAGR) of 8.5%, the expansion during the forecast period can be credited to progress in immunotherapy, precision medicine, personalized therapies, and emerging targeted therapies, as well as the implementation of artificial intelligence (AI) and patient-focused methods. Noteworthy trends throughout the forecast period incorporate liquid biopsy technologies, research in precision medicine and biomarkers, combined therapies, patient-centric and supporting treatments, and the utilization of minimally invasive surgical strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp

Which is the Largest Company in the Intestine Cancer Therapeutics Market?

Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited

What Are the Main Market Drivers in the Intestine Cancer Therapeutics Industry?

The rise in instances of hereditary colorectal cancer syndromes is set to impel the progression of the intestine cancer therapeutics market. These syndromes can increase a person’s likelihood of getting colorectal cancer, which includes both colon or rectal cancer. The value of these syndromes in intestinal cancer therapeutics lies in the insight they offer about specific genetic changes that significantly elevate the colorectal cancer risk. As per the World Health Organization, a Switzerland-based international body, predictions for July 2023 suggest that by 2040, the instances of hereditary colorectal cancer will mount noticeably, forecasting around 3.2 million new cases and 1.6 million deaths on an annual basis. This indicates a 63% and 73% surge in new instances and fatalities respectively, relative to the existing levels. Thus, the escalating prevalence of hereditary colorectal cancer syndromes is energizing the progression of the intestine cancer therapeutics market. Personalized medicine is revolutionizing the intestine cancer therapeutics market and the escalating demand for such individualized treatment is predicted to hasten the growth of this market. This approach to medical care customizes healthcare decisions, procedures, interventions, and drug therapies according to the distinctive attributes of the patient. In the realm of intestine cancer therapeutics, personalized medicine modulates such treatment methodologies based on the genetic and molecular factors of individual patients. This leads to more effective therapies with reduced side-effects. According to the Personalized Medicine Coalition, a professional membership organization based in the US, the Center for Drug Evaluation and Research under the Food and Drug Administration approved 37 new molecular entities (NMEs) in 2022. Among the 35 therapeutic NMEs, nearly 34%, corresponding to 12, were categorized as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the amplified demand for personalized medicine is propelling the growth of the intestine cancer therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13231&type=smp

How Is the Intestine Cancer Therapeutics Market Segments Structured?

The intestine cancer therapeutics market covered in this report is segmented –

1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications

Subsegments:

1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines

2) By Chemotherapy: Adjuvant Chemotherapy, Neoadjuvant Chemotherapy, Palliative Chemotherapy

3) By Other Treatments: Targeted Therapy, Radiation Therapy, Surgery, Hormone Therapy

What Strategic Trends Are Transforming the Intestine Cancer Therapeutics Market?

Notable entities in the intestinal cancer therapeutics market are inventing ground-breaking products like Lonsurf and getting endorsed to cater to a broader clientele, thereby driving more sales and boosting their revenue. LONSURF unifies two medications, trifluridine and tipiracil and is used to treat adult patients undergoing metastatic colorectal cancer. For example, in August 2023, Taiho Oncology Inc., a pharmaceutical company based in the US, got the green light for Lonsurf from the US Food and Drug Administration. Lonsurf is dispensed through a single oral tablet. The mechanism of trifluridine involves hindering the growth of cancer cells, and tipiracil extends the effectiveness of trifluridine by slowing its breakdown process in the body. The authorization of Lonsurf grants patients suffering from metastatic colorectal cancer and other qualified forms of cancer with a fresh treatment alternative, which can potentially enhance their health outcomes and quality of life.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Which Global Regions Offer the Highest Growth in the Intestine Cancer Therapeutics Market?

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13231

This Report Delivers Insight On:

1. How big is the intestine cancer therapeutics market, and how is it changing globally?

2. Who are the major companies in the intestine cancer therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the intestine cancer therapeutics market right now?

4. Which products or customer segments are growing the most in the intestine cancer therapeutics market?

5. What factors are helping or slowing down the growth of the intestine cancer therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model